Some of those may have doubled up but im sure everyone can work it out. The EOP reads as it is, end of phase meeting Q4 which i think it will be the fda telling Alterity what path they can or need to walk next once they have collaberated the full phase 2 results (201-202) which can only be done after phase 2 202 topline data is released mid year . It also states that companies will have multiple meetings with fda in between. Everything seems to be cruising along as it should be without corners being cut as far as I can tell.
my thoughts not yours
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $12.66K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 4352071 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 8220041 | 19 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |